Vivoryon的新药显示,有希望改善老年病人的肾功能,并准备进一步试验。 Vivoryon's new drug shows promise in improving kidney function in elderly patients, set for further trials.

Vivoryon治疗学为其药物varoglutamstat提供了很有希望的数据,表明该药物大大改善了老年病人的肾功能。 Vivoryon Therapeutics has presented promising data for its drug varoglutamstat, showing it significantly improves kidney function in elderly patients. 该药物是首例抑制谷氨基环曲酶的药物,在两次独立的试验中证明了这些好处。 The drug, which is the first of its kind to inhibit glutaminyl cyclase, demonstrated these benefits in two independent trials. Vivoryon计划进行以糖尿病肾病患者为重点的第2b阶段试验,以进一步评估其效果。 Vivoryon plans to conduct a Phase 2b trial focusing on patients with diabetic kidney disease to further assess its effectiveness.